1MRKX Stock Chart & Stats
€115.68
-€0.22(-0.19%)
At close: 4:00 PM EDT
€115.68
-€0.22(-0.19%)
Day’s Range― - ―
52-Week Range€53.01 - €165.00
Previous CloseN/A
Volume82.00
Average Volume (3M)87.00
Market Cap
€278.84B
Enterprise Value€340.75K
Total Cash (Recent Filing)€5.70B
Total Debt (Recent Filing)€49.12B
Price to Earnings (P/E)36.6
Beta0.34
Next Earnings
Oct 29, 2026EPS Estimate
1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.56
Shares Outstanding2,469,824,500
10 Day Avg. Volume49
30 Day Avg. Volume87
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€118.95Price Target Upside2.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)2.42
Revenue Forecast (FY)€58.08B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthSustained FCF near $14.1B (TTM) and recent growth provide durable internal funding for R&D, dividends, buybacks, and M&A without immediate reliance on equity issuance. Strong cash conversion underpins capital allocation flexibility and resilience through product cycles.
High Margins And Operating ProfitabilityVery healthy gross and operating margins reflect scale, pricing power, and efficient manufacturing. Margin durability supports reinvestment in pipelines and commercial launches, enabling sustained profitability even with modest revenue growth and protecting cash flows over the medium term.
Commercial Franchise And Pipeline MomentumA leading oncology franchise (KEYTRUDA) plus active regulatory filings and approvals provide recurring revenues and multi-year growth optionality. Combined commercial scale and regulatory cadence create a durable competitive moat and multiple future launch catalysts to sustain mid-term revenue.
Bears Say
Large One-Time Acquisition ChargeA $9B one-time charge materially distorts GAAP earnings, depressed reported equity and drove a negative tax impact. Large acquisition-related write-offs reveal integration and valuation risks that can reduce capital available for ops or force financing choices, weakening near-term financial clarity.
Elevated LeverageDebt-to-equity near 1.07 indicates meaningful reliance on debt financing versus peers. Higher leverage reduces the firm's buffer against profit volatility, increases interest exposure, and limits optionality for large BD investments or defensive spend if margins or cash flows deteriorate.
Clinical Setback In Key ProgramFailure of LITESPARK-012 to meet PFS and OS endpoints weakens visibility on a specific oncology growth path and raises binary R&D risk. Clinical setbacks can necessitate reallocation of R&D resources, slow near-term launch cadence, and reduce the probability of incremental long-term revenue from that program.
Merck & Company News
1MRKX FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €53.01 and its highest was €165.00 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is €278.84B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 29, 2026 which is in 86 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Aug 04, 2026. The company reported -€0.113 earnings per share for the quarter, beating the consensus estimate of -€0.235 by €0.122.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company does not currently pay dividends.
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.97.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,469,824,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -€0.113 in its last earnings report, beating expectations of -€0.235. Following the earnings report the stock price went down -0.18%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in IT:1MRKX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€118.95 (2.82% Upside)
€118.95 (2.82% Upside)
Blogger Sentiment
Bullish
IT:1MRKX Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.04%
12-Months-Change
Fundamentals
Return on Equity
2.57%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
1MRKX Company Deck
1MRKX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and scientific story: core revenue growth (Q2 +5%), several strong product performances (KEYTRUDA, WELIREG, WINREVAIR), meaningful vaccine and pneumococcal momentum, multiple important regulatory approvals and positive Phase III readouts (LIPFENDRA approval, sac-TMT, tulisokibart induction, islatravir combos), and raised/narrowed revenue guidance. Offsetting these positives are material one-time charges from the Terns acquisition that produced a GAAP loss and drove a volatile tax rate, margin and expense pressure, one clinical setback (SSc-ILD), and some near-term commercial headwinds (OHTUVAYRE unwind, moderating KEYTRUDA U.S. growth). Overall, management emphasized pipeline derisking, continued launches, and long-term opportunity, while acknowledging short-term impacts from the acquisition and inventory/reserve dynamics.View all IT:1MRKX earnings summaries1MRKX Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
1MRKX Stock 12 Month Forecast
Average Price Target
€118.95
▲(2.82% Upside)